EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a pharmaceutical company that develops and commercializes therapies for treatment of eye disorders. The company utilizes its Duraset platform, a miniaturized, injectable, and sustained delivery system to develop its product. Its pipeline products includes EYP-1901, an investigational sustained delivery intravital anti-VEGF treatment that targets wet age-related macular degeneration (Wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macularedema (DME). The company also markets its product such as Yutiq, a fluocinolone acetonide intravitreal implant to treat chronic non-infectious uvetis; and Dexycu for treatment of postoperative inflammation. EyePoint is headquartered in Watertown, Massachusetts, the US.
Headquarters
United States of America
Address
480 Pleasant St Ste B300, Watertown, Massachusetts, 02472-2468
Website
eyepointpharma.com
Telephone
1 617 9265000
No of Employees
121
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EYPT (NASD)
Revenue (2022)
$46.0M
11.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
30.8%
(2022 vs 2021)
Market Cap*
$834.7M
Net Profit Margin (2022)
XYZ
37.7%
(2022 vs 2021)
* As of and is in US$
EyePoint Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Commercial |
| Yutiq: |
| Chronic Non-Infectious Uvetis |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In February, the company entered into an agreement with Rallybio to evaluate sustained delivery of Rallybio’s inhibitor of complement component 5 (C5) using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. |
| 2020 | Contracts/Agreements | In February, the company signed an agreement to acquire DEXYCU from Vision Center Network of America. |
| 2018 | Acquisitions/Mergers/Takeovers | In March, the company announced the acquisition of bio-pharmaceutical company, Icon Bioscience Inc. |
Competitor Comparison
| Key Parameters | EyePoint Pharmaceuticals Inc | Eyenovia Inc | Radius Health Inc | Outlook Therapeutics Inc |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Watertown | New York | Boston | Iselin |
| State/Province | Massachusetts | New York | Massachusetts | New Jersey |
| No. of Employees | 121 | 57 | - | 24 |
| Entity Type | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Goran Ando | Chairman | Executive Board | 2018 | - |
| Nancy S. Lurker | Vice Chairman | Executive Board | 2023 | - |
| Jay S. Duker, M.D | Director; President; Chief Executive Officer | Executive Board | 2023 | - |
| George O. Elston | Chief Financial Officer | Senior Management | 2019 | - |
| Said Saim | Chief Technology Officer | Senior Management | 2019 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer